Nuvation Bio, listed via SPAC in 2021, and acquired AnHeart Therapeutics last year, gaining taletrectinib, a promising ROS1 inhibitor indicated for non-small cell lung cancer. The FDA has accepted ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback